{"filing":{"accession_number":"0001104659-26-111170","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"tm2626237d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926111170/tm2626237d1_8k.htm"},"events":[{"id":35327,"run_id":32536,"accession_number":"0001104659-26-111170","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"TransCode announced updated Phase 1a clinical trial data for TTX-MC138 showing a 71.4% stable disease rate, disease control extending through six months, and three patients progression-free at one year, with no dose-limiting toxicities. This is a material clinical milestone for a clinical-stage immuno-oncology company, demonstrating positive efficacy and safety signals that support advancement to Phase 2a trials. While not a traditional earnings release (the company is pre-revenue), this clinical data disclosure is a significant operational and strategic milestone that would affect investor assessment of the drug candidate's therapeutic potential.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39344,"accession_number":"0001104659-26-111170","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TransCode announced updated Phase 1a clinical trial data for TTX-MC138 showing a 71.4% stable disease rate, disease control extending through six months, and three patients progression-free at one year, with no dose-limiting toxicities. This is a material clinical milestone for a clinical-stage immuno-oncology company, demonstrating positive efficacy and safety signals that support advancement to Phase 2a trials. While not a traditional earnings release (the company is pre-revenue), this clinical data disclosure is a significant operational and strategic milestone that would affect investor assessment of the drug candidate's therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:57.356144+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39344,"accession_number":"0001104659-26-111170","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"TransCode announced updated Phase 1a clinical trial data for TTX-MC138 showing a 71.4% stable disease rate, disease control extending through six months, and three patients progression-free at one year, with no dose-limiting toxicities. This is a material clinical milestone for a clinical-stage immuno-oncology company, demonstrating positive efficacy and safety signals that support advancement to Phase 2a trials. While not a traditional earnings release (the company is pre-revenue), this clinical data disclosure is a significant operational and strategic milestone that would affect investor assessment of the drug candidate's therapeutic potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:17:57.356144+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-09-28"}]}